Iovance Sparks More Optimism About Lifileucel’s Commercial Potential With New Analysis

 
• By Alaric DeArment
Iovance presented updated data from its Phase II study of lifileucel at SITC • Source: Shutterstock

More from Immuno-oncology

More from Anticancer